{"title":"The past, present and future of lipidlowering therapy","authors":"Osman Najam, G. Lambert, K. Ray","doi":"10.2217/clp.15.40","DOIUrl":null,"url":null,"abstract":"Abstract Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. Dyslipidemia is a major risk factor, with elevated plasma lipids having a well-established relationship with CVD. While lifestyle modification and statins have played an important role in reducing risk, many patients develop CVD despite best care. Statins remain the most prescribed lipid-lowering therapy, yet many patients may require additional therapies. Fibrates, ezetimibe and bile acid sequestrants have been extensively investigated thus far, with mixed results. Newer classes of lipid modifying therapy include monoclonal antibodies to PCSK9, lomitapide and cholesterol ester transfer protein inhibitors. In this review, we revisit the history of lipid-lowering therapy, the pharmacotherapies currently used and future direction of research.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"43 1","pages":"481 - 498"},"PeriodicalIF":0.0000,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.15.40","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 5
Abstract
Abstract Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. Dyslipidemia is a major risk factor, with elevated plasma lipids having a well-established relationship with CVD. While lifestyle modification and statins have played an important role in reducing risk, many patients develop CVD despite best care. Statins remain the most prescribed lipid-lowering therapy, yet many patients may require additional therapies. Fibrates, ezetimibe and bile acid sequestrants have been extensively investigated thus far, with mixed results. Newer classes of lipid modifying therapy include monoclonal antibodies to PCSK9, lomitapide and cholesterol ester transfer protein inhibitors. In this review, we revisit the history of lipid-lowering therapy, the pharmacotherapies currently used and future direction of research.
期刊介绍：
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
